Overview

A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients

Status:
Completed
Trial end date:
2018-07-30
Target enrollment:
Participant gender:
Summary
This study evaluates the optimal dosage and safety of Dalteparin when used as an anticoagulant for hemodialysis therapies.
Phase:
Phase 4
Details
Lead Sponsor:
Lawson Health Research Institute
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin